| Identification | Back Directory | [Name]
"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " | [CAS]
1384097-27-1 | [Synonyms]
"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide "
3-Pyridinesulfonamide, 5-[(3S)-2-amino-3,4-dihydro-4-oxo-3-[2-(trifluoromethyl)phenyl]-6-quinazolinyl]-N-(2,4-difluorophenyl)-2-methoxy- | [Molecular Formula]
C27H18F5N5O4S | [MDL Number]
MFCD29770785 | [MOL File]
1384097-27-1.mol | [Molecular Weight]
603.52 |
| Hazard Information | Back Directory | [Uses]
(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC50 of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model[1]. | [IC 50]
PI4KIIIα: 8.3 (pIC50); PI4KIIIβ: 6.0 (pIC50); PI3Kα: 5.6 (pIC50); PI3Kδ: 5.6 (pIC50); PI3Kβ: 5.1 (pIC50) | [References]
[1] Leivers AL, et al., Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents. J Med Chem. 2014 Mar 13;57(5):2091-106. DOI:10.1021/jm400781h |
|
|